-
1
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
-
(2015)
N Engl J Med
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
-
2
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
-
(2015)
N Engl J Med
, vol.372
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
Dutriaux, C.4
Maio, M.5
Mortier, L.6
-
3
-
-
84941800472
-
Adaptive immune resistance: How cancer protects from immune attack
-
Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015;5:915-9.
-
(2015)
Cancer Discov
, vol.5
, pp. 915-919
-
-
Ribas, A.1
-
4
-
-
77953747963
-
The PD-1 pathway in tolerance and autoimmunity
-
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
-
(2010)
Immunol Rev
, vol.236
, pp. 219-242
-
-
Francisco, L.M.1
Sage, P.T.2
Sharpe, A.H.3
-
5
-
-
84894082425
-
Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues
-
Honda T, Egen JG, Lammermann T, Kastenmuller W, Torabi-Parizi P, Germain RN. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 2014;40:235-47.
-
(2014)
Immunity
, vol.40
, pp. 235-247
-
-
Honda, T.1
Egen, J.G.2
Lammermann, T.3
Kastenmuller, W.4
Torabi-Parizi, P.5
Germain, R.N.6
-
7
-
-
33749038866
-
Reversal of the TCR stop signal by CTLA-4
-
Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006;313:1972-5.
-
(2006)
Science
, vol.313
, pp. 1972-1975
-
-
Schneider, H.1
Downey, J.2
Smith, A.3
Zinselmeyer, B.H.4
Rush, C.5
Brewer, J.M.6
-
8
-
-
84927161437
-
The immune checkpoint inhibitors: Where are we now?
-
Webster RM. The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov 2014;13:883-4.
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 883-884
-
-
Webster, R.M.1
-
9
-
-
84880706152
-
Oncology meets immunology: The cancer-immunity cycle
-
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10.
-
(2013)
Immunity
, vol.39
, pp. 1-10
-
-
Chen, D.S.1
Mellman, I.2
-
10
-
-
84880507665
-
Mutational heterogeneity in cancer and the search for new cancer-associated genes
-
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.
-
(2013)
Nature
, vol.499
, pp. 214-218
-
-
Lawrence, M.S.1
Stojanov, P.2
Polak, P.3
Kryukov, G.V.4
Cibulskis, K.5
Sivachenko, A.6
-
11
-
-
84943516465
-
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
-
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015;350:207-11.
-
(2015)
Science
, vol.350
, pp. 207-211
-
-
Van Allen, E.M.1
Miao, D.2
Schilling, B.3
Shukla, S.A.4
Blank, C.5
Zimmer, L.6
-
12
-
-
84962301577
-
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
-
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016;351:1463-9.
-
(2016)
Science
, vol.351
, pp. 1463-1469
-
-
McGranahan, N.1
Furness, A.J.2
Rosenthal, R.3
Ramskov, S.4
Lyngaa, R.5
Saini, S.K.6
-
13
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
-
(2015)
N Engl J Med
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
Bartlett, B.R.4
Kemberling, H.5
Eyring, A.D.6
-
14
-
-
84957093642
-
Loss of PTEN promotes resistance to T cell-mediated immunotherapy
-
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016;6:202-16.
-
(2016)
Cancer Discov
, vol.6
, pp. 202-216
-
-
Peng, W.1
Chen, J.Q.2
Liu, C.3
Malu, S.4
Creasy, C.5
Tetzlaff, M.T.6
-
15
-
-
84960842480
-
MYC regulates the antitumor immune response through CD47 and PD-L1
-
Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 2016;352:227-31.
-
(2016)
Science
, vol.352
, pp. 227-231
-
-
Casey, S.C.1
Tong, L.2
Li, Y.3
Do, R.4
Walz, S.5
Fitzgerald, K.N.6
-
16
-
-
84902124970
-
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
-
Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014;20:607-15.
-
(2014)
Nat Med
, vol.20
, pp. 607-615
-
-
Motz, G.T.1
Santoro, S.P.2
Wang, L.P.3
Garrabrant, T.4
Lastra, R.R.5
Hagemann, I.S.6
-
17
-
-
38049000452
-
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
-
Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008;14:28-36.
-
(2008)
Nat Med
, vol.14
, pp. 28-36
-
-
Buckanovich, R.J.1
Facciabene, A.2
Kim, S.3
Benencia, F.4
Sasaroli, D.5
Balint, K.6
-
19
-
-
84878831880
-
Posttranscriptional control of T cell effector function by aerobic glycolysis
-
Chang CH, Curtis JD, Maggi LBJr, Faubert B, Villarino AV, O'Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013;153:1239-51.
-
(2013)
Cell
, vol.153
, pp. 1239-1251
-
-
Chang, C.H.1
Curtis, J.D.2
Maggi, L.B.3
Faubert, B.4
Villarino, A.V.5
O'Sullivan, D.6
-
20
-
-
84890281217
-
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
-
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013;110:20212-7.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 20212-20217
-
-
Feig, C.1
Jones, J.O.2
Kraman, M.3
Wells, R.J.4
Deonarine, A.5
Chan, D.S.6
-
21
-
-
84857826513
-
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
-
Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012;122:899-910.
-
(2012)
J Clin Invest
, vol.122
, pp. 899-910
-
-
Salmon, H.1
Franciszkiewicz, K.2
Damotte, D.3
Dieu-Nosjean, M.C.4
Validire, P.5
Trautmann, A.6
-
22
-
-
84978476944
-
FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling
-
Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res 2016;76:4124-35.
-
(2016)
Cancer Res
, vol.76
, pp. 4124-4135
-
-
Yang, X.1
Lin, Y.2
Shi, Y.3
Li, B.4
Liu, W.5
Yin, W.6
-
23
-
-
84958124766
-
Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy
-
Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016;44:343-54.
-
(2016)
Immunity
, vol.44
, pp. 343-354
-
-
Pfirschke, C.1
Engblom, C.2
Rickelt, S.3
Cortez-Retamozo, V.4
Garris, C.5
Pucci, F.6
-
24
-
-
84926525215
-
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
-
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373-7.
-
(2015)
Nature
, vol.520
, pp. 373-377
-
-
Twyman-Saint Victor, C.1
Rech, A.J.2
Maity, A.3
Rengan, R.4
Pauken, K.E.5
Stelekati, E.6
-
25
-
-
33646704729
-
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
-
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203:1259-71.
-
(2006)
J Exp Med
, vol.203
, pp. 1259-1271
-
-
Reits, E.A.1
Hodge, J.W.2
Herberts, C.A.3
Groothuis, T.A.4
Chakraborty, M.5
Wansley, E.K.6
-
26
-
-
84964344569
-
Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition
-
Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 2016;44:924-38.
-
(2016)
Immunity
, vol.44
, pp. 924-938
-
-
Salmon, H.1
Idoyaga, J.2
Rahman, A.3
Leboeuf, M.4
Remark, R.5
Jordan, S.6
-
27
-
-
84928195112
-
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
-
Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015;348:803-8.
-
(2015)
Science
, vol.348
, pp. 803-808
-
-
Carreno, B.M.1
Magrini, V.2
Becker-Hapak, M.3
Kaabinejadian, S.4
Hundal, J.5
Petti, A.A.6
-
28
-
-
84976871907
-
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
-
Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 2016;22:851-60.
-
(2016)
Nat Med
, vol.22
, pp. 851-860
-
-
Jiang, H.1
Hegde, S.2
Knolhoff, B.L.3
Zhu, Y.4
Herndon, J.M.5
Meyer, M.A.6
-
29
-
-
84905994658
-
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
-
Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014;111:11774-9.
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, pp. 11774-11779
-
-
Kim, K.1
Skora, A.D.2
Li, Z.3
Liu, Q.4
Tam, A.J.5
Blosser, R.L.6
-
30
-
-
84975520175
-
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
-
Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, et al. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 2016;7:18508-20.
-
(2016)
Oncotarget
, vol.7
, pp. 18508-18520
-
-
Luheshi, N.M.1
Coates-Ulrichsen, J.2
Harper, J.3
Mullins, S.4
Sulikowski, M.G.5
Martin, P.6
|